Pi – Applied Artificial Intelligence for diagnosing prostate cancer from MRI
What is Pi?
Pi is an AI and machine learning based software system that detects and reports the presence of prostate cancer lesions from MR scans (MRI).
Pi is intended to augment a radiologist’s interpretation of prostate MRI in three ways
- Improve patient selection for biopsy
This is achieved by outputting a risk score aiming for both high negative predictive value (NPV) and specifity, to reduce unnecessary biopsies and over diagnosis if insignificant cancers
- Improve identification of targets for biopsy
This involves identifying candidate regions of interest with high NPV, to help ensure that all areas of suspicion are targeted for biopsy and help reduce underdiagnosis (missed clinically significant cancers)
- Provide high quality segmentations
Outputing machine generated segmentations with high DICE score, for use in volume estimation and biopsy targeting
To learn more, you can access a video and paper frpm EuSoMII Virtual Annual Meeting, 24 October 2020 and a published research paper by clicking the links below
Our Partners
We collaborate with Cambridge University, we are a partner in the ReIMAGINE prostate imaging trial, are in the process of establishing collaborative partnerships with several UK NHS Trust hospitals to help further develop and validate and test Pi, our AI system for detecting prostate cancer from MRI.
